Schizo-Obsessive Disorder: Case Study
Case Presentation A 20-year-old patient, high school student, lives with family. Nicotine addict, confirms occasional alcohol and marijuana use. In november 2019, the patient’s mental status was deteriorating. Patient was in ambulatory treatment with olanzapine and fluoxetine, but with no satisfactory results, which was the reason for the first psychiatric hospitalization in august 2020. Symptoms […]
Ultra-Long-Acting Oral Antipsychotic for Treatment of Schizophrenia
Conference – American Society of Clinical Psychopharmacology (ASCP) 2021 (June 1-4, 2021) Date – June 03, 2021 Mode – Virtual A new phase II study suggested improved quality of life and treatment adherence in schizophrenic patients with a novel, ultra-long-acting formulation of risperidone (LYN-005). The study comprised of 32 schizophrenia patients received immediate-release (IR) risperidone […]
Ultra-Long-Acting Oral Antipsychotic for Treatment of Schizophrenia
A new phase II study suggested improved quality of life and treatment adherence in schizophrenic patients with a novel, ultra-long-acting formulation of risperidone (LYN-005). The study comprised of 32 schizophrenia patients received immediate-release (IR) risperidone 2 mg or 4 mg and were randomized to either of the four groups, IR risperidone-matched placebo and LYN-005 at […]
Comorbid Major Depressive Disorder In Schizophrenic Patients
Introduction Major depressive disorder (MDD) plays a key role in the prognosis of schizophrenia and increases suicidal tendencies while hampering the quality of life. Objective To determine the prevalence of schizophrenia-MDD in stabilized schizophrenia real-world outpatients and to evaluate the associated factors dictating the schizophrenia-MDD prevalence. Study Design A Systematic Review and Meta-Analysis Methods Medline, […]